| Company Name: |
DC Chemicals |
| Tel: |
021-58447131 13564518121 |
| Email: |
doncunbiosci@gmail.com |
OTS186935 manufacturers
- OTS186935
-
- $2500.00
-
2026-07-16
- CAS:2093400-18-9
- Purity:
- Supply Ability: 10g
- OTS186935
-
- $2500.00
-
2026-07-15
- CAS:2093400-18-9
- Purity:
- Supply Ability: 10g
- OTS186935
-
- $2500.00
-
2025-07-18
- CAS:2093400-18-9
- Purity:
- Supply Ability: 10g
|
| | OTS186935 Basic information |
| Product Name: | OTS186935 | | Synonyms: | OTS-186935;OTS 186935;OTS186935;4-Pyridinemethanamine, N-[(3S)-1-[2-(5-chloro-2,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-7-yl]-3-pyrrolidinyl]- | | CAS: | 2093400-18-9 | | MF: | C25H26ClN5O2 | | MW: | 463.96 | | EINECS: | | | Product Categories: | | | Mol File: | 2093400-18-9.mol |  |
| | OTS186935 Chemical Properties |
| density | 1.33±0.1 g/cm3(Predicted) | | pka | 7.32±0.50(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | OTS186935 Usage And Synthesis |
| Description | OTS186935 is a protein methyltransferase SUV39H2 inhibitor. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. It regulates the production of γ-H2AX in cancer cells. | | Uses | OTS186935 is a potent protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 regulates the production of γ-H2AX in cancer cells[1]. | | in vivo | OTS186935 (10 mg/kg or 25 mg/kg; intravenously; once daily for 14 days) exhibits growth suppressive effects in human cancer cell line derived xenograft models[1]. | Animal Model: | Female NOD.CB17-Prkdcscid/J mice (bearing MDA-MB-231 cells )[1] | | Dosage: | 10 mg/kg | | Administration: | Intravenously; once daily for 14 days | | Result: | Tumor growth inhibition of 42.6% on day 14.
|
| Animal Model: | Female BALB/cAJcl-nu/nu mice (bearing A549 cells)[1] | | Dosage: | 25 mg/kg | | Administration: | Intravenously; once daily for 14 days | | Result: | Yielded a tumor growth inhibition of 60.8% without significant body weight loss or toxicity.
|
| | References | [1] Vougiouklakis T, et al. Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX. Oncotarget. 2018 Aug 7;9(61):31820-31831. DOI:10.18632/oncotarget.25806 |
| | OTS186935 Preparation Products And Raw materials |
|